LLY
Eli Lilly and Company
NYSE: LLY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$1,144.68
-0.39% today
Updated 2026-06-09
Market cap
$948.95B
P/E ratio
37.74
P/S ratio
13.13x
EPS (TTM)
$28.20
Dividend yield
0.58%
52W range
$619 – $1,149
Volume
3.2M
WallStSmart proprietary scores
78
out of 100
Grade: B+
Buy
Investment rating
10.0
Growth
A+6.0
Quality
B10.0
Profitability
A+5.0
Valuation
C+6/9
Piotroski F-Score
Moderate
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →209 stocks currently score above 75
Price targets
Analyst target
$1,218.00
+6.41%
12-Month target
$686.31
-40.04%
Intrinsic (DCF)
—
Margin of safety
—
6 Strong Buy18 Buy5 Hold1 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 35.00% — above average
+ ROE 81.01% — strong efficiency
+ Free cash flow $3.01B — positive
+ Revenue growth 55.50% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $28.54B | $34.12B | $45.04B | $65.18B | $72.25B | $83.5B |
| Net income | $6.24B | $5.24B | $10.59B | $20.64B | $7.40B | — |
| EPS | — | — | — | — | $28.20 | $37.50 |
| Free cash flow | $4.60B | $-3.15B | $414.30M | $8.97B | $3.01B | — |
| Profit margin | 21.88% | 15.36% | 23.51% | 31.66% | 35.00% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-18 | SULZBERGER, GABRIELLE | Buy | 5 | $988.09 |
| 2026-05-18 | LUCIANO, JUAN R | Buy | 16 | $988.09 |
| 2026-05-18 | FYRWALD, J ERIK | Buy | 10 | $988.09 |
Peer comparison
Smart narrative
Eli Lilly and Company trades at $1,144.68. representing a P/E of 37.74x trailing earnings. Our Smart Value Score of 78/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 2.06, it sits in the grey zone. TTM revenue stands at $72.25B. with profit margins at 35.00%.
Frequently asked questions
What is Eli Lilly and Company's stock price?
Eli Lilly and Company (LLY) trades at $1,144.68, on a P/E of 37.7x and a P/S of 13.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Eli Lilly and Company overvalued?
Eli Lilly and Company carries a Smart Value Score of 78/100 (Grade B+), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Eli Lilly and Company (LLY)?
The 12-month analyst consensus target is $1,218.00, about 6.4% above the current $1,144.68. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of LLY by 2030?
Our research-backed model puts the 2030 base case at $1,943.85, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Eli Lilly and Company's revenue?
Eli Lilly and Company's trailing twelve-month revenue is $72.25B, and our model projects it reaching about $176.00B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Eli Lilly and Company's Altman Z-Score is 2.06, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio13.13x
ROE81.01%
Beta0.48
50D MA$960.91
200D MA$941.45
Shares out0.89B
Float0.89B
Short ratio—
Avg volume3.2M
Performance
1 week+4.88%
1 month+17.21%
3 months+13.35%
YTD+5.45%
1 year+40.91%
3 years+158.64%
5 years—